Hims & Hers shares plunge 12 amid allegations of GLP-1 drug sourcing from shady supplier

Get the Full StoryA new report criticized Hims GLP-1 offerings, saying that they re being acquired through a shady supplier.

Roughly a month after announcing that it would offer GLP-1 injectable weight-loss drugs comparable to the popular drugs Ozempic and Monjaro, Hims & Hers Health shares are taking a beating after a new report criticized those offerings, saying that they re being acquired through a shady supplier.

Share: